Boston Biomedical, Inc. is a leading developer of next-generation cancer therapeutics designed to inhibit cancer stemness pathways and modify immune responses. Tolero Pharmaceuticals, Inc. is a leader in developing novel therapeutics to inhibit biological drivers of hematologic and oncologic diseases and target drug resistance and transcription pathways. Both companies are based in the United States and are wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Please visit www.BostonBiomedical.com and www.ToleroPharma.com.